Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor | Zendy

N. Galliker | Zendy; Carla Murer | Zendy; Jivko Kamarashev | Zendy; Reinhard Dummer | Zendy; Simone M. Goldinger | Zendy

Open Access

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

Author(s) -

N. Galliker,

Carla Murer,

Jivko Kamarashev,

Reinhard Dummer,

Simone M. Goldinger

Publication year - 2015

Publication title -

european journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.48

H-Index - 71

eISSN - 1952-4013

pISSN - 1167-1122

DOI - 10.1684/ejd.2014.2512

Subject(s) - medicine , metastatic melanoma , mek inhibitor , melanoma , panniculitis , cancer research , dermatology , oncology , phosphorylation , mapk/erk pathway , biochemistry , chemistry

Treatment with selective BRAF or MEK inhibitors is frequently associated with cutaneous toxicities, including squamous cell carcinoma (SCC), papillomas and rash. These cutaneous adverse effects are typically observed at a lower incidence during combined BRAF and MEK inhibitor therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research